(Q34168931)

31 July 2017

1 reference

title

Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer (English)

1 reference

31 July 2017

1 reference

1 reference

1

Antona J Wagstaff

1 reference

31 July 2017

Tim Ibbotson

2

1 reference

31 July 2017

Karen L Goa

series ordinal

3

1 reference

31 July 2017

publication date

1 January 2003

1 reference

31 July 2017

1 reference

31 July 2017

volume

63

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

217-236

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363020-00009

31 July 2017

exact match

0 references

cites work

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine

1 reference

12 December 2020

Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: biological synergy or an artefact of trial design?

1 reference

12 December 2020

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

1 reference

12 December 2020

Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer

1 reference

12 December 2020

State-of-the-art chemotherapy for advanced breast cancer.

1 reference

12 December 2020

1 reference

12 December 2020

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

1 reference

12 December 2020

Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models

1 reference

12 December 2020

Update: NCCN practice guidelines for the treatment of breast cancer. National Comprehensive Cancer Network

1 reference

12 December 2020

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

1 reference

12 December 2020

Use of capecitabine as first-line therapy in patients with metastatic breast cancer relapsing after high-dose chemotherapy and autologous stem cell support

1 reference

12 December 2020

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer

1 reference

12 December 2020

Clinical pharmacokinetics of capecitabine

1 reference

12 December 2020

Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient

1 reference

12 December 2020

Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites

1 reference

12 December 2020

A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug

1 reference

12 December 2020

Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts

1 reference

12 December 2020

Strategies of medical treatment for metastatic breast cancer (Review).

1 reference

12 December 2020

Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients

1 reference

12 December 2020

Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force

1 reference

12 December 2020

Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine)

1 reference

12 December 2020

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

12 December 2020

Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond

1 reference

12 December 2020

Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience

1 reference

12 December 2020

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

1 reference

12 December 2020

Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function

1 reference

12 December 2020

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

12 December 2020

Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models

1 reference

12 December 2020

Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study

1 reference

12 December 2020

Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies

1 reference

12 December 2020

The current status of docetaxel for metastatic breast cancer.

1 reference

12 December 2020

Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.

1 reference

12 December 2020

10.2165/00003495-200363020-00009

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1042288986

0 references

1 reference